Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
acute toxicity: other routes
Type of information:
experimental study
Adequacy of study:
supporting study
Study period:
Not reported
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
other: Summary information only
Cross-reference
Reason / purpose for cross-reference:
reference to same study

Data source

Reference
Reference Type:
other company data
Title:
Unnamed
Year:
1970
Report date:
1970

Materials and methods

Principles of method if other than guideline:
Not reported
GLP compliance:
not specified
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
Trisodium 2-(carboxylatomethyl(2-hydroxyethyl)amino)ethyliminodi(acetate)
EC Number:
205-381-9
EC Name:
Trisodium 2-(carboxylatomethyl(2-hydroxyethyl)amino)ethyliminodi(acetate)
Cas Number:
139-89-9
Molecular formula:
C10H18N2O7.3Na
IUPAC Name:
trisodium [{2-[bis(carboxylatomethyl)amino]ethyl}(2-hydroxyethyl)amino]acetate
Details on test material:
Not reported

Test animals

Species:
mouse
Strain:
not specified
Sex:
not specified
Details on test animals or test system and environmental conditions:
Not reported

Administration / exposure

Route of administration:
intraperitoneal
Vehicle:
not specified
Details on exposure:
Not reported
Doses:
Not reported
No. of animals per sex per dose:
Not reported
Control animals:
not specified
Details on study design:
Not reported
Statistics:
Not reported

Results and discussion

Effect levels
Sex:
not specified
Dose descriptor:
LD50
Effect level:
ca. 330 other: mm^3
Based on:
not specified
Mortality:
Not reported
Clinical signs:
Symptoms: dyspnea, staggering, convulsions, diarrhea
Body weight:
Not reported
Gross pathology:
individual abdominal adhesions
Other findings:
Not reported

Any other information on results incl. tables

Not applicable

Applicant's summary and conclusion

Conclusions:
Trilon D fluseig was found to have an acute oral LD50 of about 330 mm^3 to mice exposed via intraperitoneal injection.
Executive summary:

Trilon D fluseig was found to have an acute oral LD50 of about 330 mm^3 to mice exposed via intraperitoneal injection.